|
Match
|
Document |
Document Title |
|
|
US20140294843 |
DIAGNOSIS AND TREATMENT OF COPD
Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a... |
|
|
US20140248273 |
VACCINE BASED ON STAPHYLOCOCCAL SUPERANTIGEN-LIKE 3 PROTEIN (SSL3)
The present invention relates to the field of vaccinology, especially of vaccines against Staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a... |
|
|
US20110014190 |
USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO PROMOTE TRANSPLANTATION TOLERANCE
The invention relates to methods of preventing, treating, ameliorating and otherwise inhibiting organ or transplant rejection in a patient by administering B Lymphocyte Stimulator antagonists. In... |
|
|
US20130064828 |
Chimeric Vaccine for Haemophilus Influenzae-Induced Disease
The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention... |
|
|
US20110044975 |
TREATMENT OF PRION PROTEIN RELATED DISEASES
According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective... |
|
|
US20150166660 |
IMMUNOMODULATION BY ANTI-CD3 IMMUNOTOXINS TO TREAT CANCERS NOT UNIFORMLY BEARING SURFACE CD3
Methods of modulating the immune systems of patients suffering from cancers that do not hear, or do not uniformly bear, surface CD3 are provided. The methods involve administering an anti-CD3... |
|
|
US20150147329 |
INFLUENZA TREATMENT AND/OR CHARACTERIZATION, HUMAN-ADAPTED HA POLYPEPTIDES; VACCINES
The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections. |
|
|
US20110158993 |
Train-R: A Cysteine Rich Member of the TNF-Receptor Family
Novel receptor in the TNF family: TRAIN-receptor. |
|
|
US20120100143 |
IMMUNOGENIC PROTEINS FROM GENOME-DERIVED OUTER MEMBRANE OF LEPTOSPIRA AND COMPOSITIONS AND METHODS BASED THEREON
Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for... |
|
|
US20110268729 |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS BY NOGO-A-ANTAGONIST
The invention relates to methods for the treatment or prophylaxis of amyotrophic lateral sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a... |
|
|
US20120263724 |
Escherichia coli o157:h7 proteins and uses thereof
Immunogenic Escherichia coli O157:H7 (0157) proteins expressed during infection of a mammal, are described. In particular, 0157 proteins expressed specifically in vivo during human and cattle... |
|
|
US20150037251 |
MAMMALIAN HOMOLOGUES OF FLOWER, THEIR USE IN CANCER DIAGNOSTICS, PREVENTION AND TREATMENT
The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing,... |
|
|
US20120020973 |
CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA... |
|
|
US20130315916 |
RESPIRATORY SYNCYTIAL VIRUS VACCINE
Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH)... |
|
|
US20150209426 |
TREATMENT OF CANCER
A method for treating breast cancer with an insulin-like growth factor (IGF) receptor antagonist in combination with exemestane and everolimus. |
|
|
US20150079095 |
PREVENTON, TREATMENT AND DIAGNOSIS OF P. GINGIVALIS INFECTION
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases. |
|
|
US20130224192 |
METHOD FOR THE PROGNOSIS OF THE PROGRESSION OF CANCER
The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or... |
|
|
US20110262446 |
USE OF IGF-II/IGF-IIE BINDING PROTEINS FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY FIBROSIS
Methods of using proteins that bind to IGF-II and/or IGF-IIE for the treatment or prevention of systemic sclerosis-associated pulmonary fibrosis are described. |
|
|
US20110280880 |
PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTION
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases. |
|
|
US20120141473 |
COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and... |
|
|
US20140356368 |
APPLICATIONS OF AN IMMUNE SYSTEM-RELEASED ACTIVATING AGENT (ISRAA)
The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the... |
|
|
US20120020974 |
OPTIMIZING ERYTHROPOIETIN THERAPY
The methods described herein can be used to identify ex ante which hemodialysis patients are likely to develop EPO resistance and therefore will require additional rHu EPO, and to provide... |
|
|
US20120237519 |
PESTVIRUS SPECIES
The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further... |
|
|
US20150232575 |
TREATMENT OF OCULAR DISEASES
Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular... |
|
|
US20140079702 |
ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of... |
|
|
US20120014955 |
Antagonists of IL-6 to raise albumin and/or lower CRP
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of... |
|
|
US20140037637 |
MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4)
The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced... |
|
|
US20150203585 |
Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System
The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating... |
|
|
US20140037630 |
METHODS FOR TREATING MICA-RELATED DISORDERS
Disclosed herein are materials and methods for treating cancer. In particular, the compositions and methods for treating cancers associated with MICA overexpression are provided. |
|
|
US20140112929 |
TUMOUR NECROSIS FACTOR RECEPTOR 1 ANTAGONISTS
The invention relates to TNFR1 binding proteins, in particular those which are capable of preventing dimerisation of TNFR1 chains, and to their use in therapy. |
|
|
US20130259869 |
REARRANGED TT VIRUS MOLECULES FOR USE IN DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER AND AUTOIMMUNITY
The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated... |
|
|
US20110305633 |
Methods for Treatment, the Prognostic Assessment and the Detection of Breast Cancer
The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer. |
|
|
US20150023912 |
COMBINATIONS OF ALBUMIN-BASED DRUG DELIVERY SYSTEMS
The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition. |
|
|
US20140212412 |
USE OF IL-33 ANTAGONISTS TO TREAT FIBROTIC DISEASE
Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of IL-33 are disclosed. |
|
|
US20120263709 |
USE OF IL-33 ANTAGONISTS TO TREAT FIBROTIC DISEASES
Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of IL-33 are disclosed. |
|
|
US20130121995 |
Compositions and Methods for Increasing Bone Mineralization
A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. |
|
|
US20110150866 |
Compositions and Methods for Increasing Bone Mineralization
A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. |
|
|
US20120030780 |
TARGETING OF SALL4 FOR THE TREATMENT AND DIAGNOSIS OF PROLIFERATIVE DISORDERS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME (MDS)
The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are... |
|
|
US20120064080 |
Human LY6-Big Molecules and Methods of Use
The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of... |
|
|
US20110020352 |
ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER
Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy. |
|
|
US20140134177 |
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in... |
|
|
US20130121993 |
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in... |
|
|
US20130115206 |
Compositions and Methods for Treating and Diagnosing Cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in... |
|
|
US20120171215 |
NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE THEREOF
The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant <1000 nM, a polynucleotide encoding such... |
|
|
US20110027284 |
NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE THEREOF
The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<1000 nM, a polynucleotide encoding such... |
|
|
US20130195870 |
ERBB3 Mutations In Cancer
The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including... |
|
|
US20130315964 |
PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING OF PRODUCTION OR AMPLIFYING OF ELIMINATION OF P24 PROTEIN
The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying of... |
|
|
US20120263726 |
Pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein
The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying of... |
|
|
US20150247206 |
Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis
The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer.... |
|
|
US20130171133 |
CANCER METHODS
A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is... |